Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX, USA.
Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Int J Psychiatry Clin Pract. 2022 Jun;26(2):183-195. doi: 10.1080/13651501.2021.1957117. Epub 2021 Aug 4.
The objective of this manuscript is to provide a comprehensive and critical overview of the current evidence on the association between Diabetes mellitus (DM) and mood disorders [i.e., Major depressive disorder (MDD) and bipolar disorder (BD)], and therapeutic opportunities.
We searched in MEDLINE (via Ovid) for placebo-controlled clinical trials published in the last 20 years that assessed drug repurposing approaches for the treatment of DM or mood disorders.
We found seven studies that aimed to verify the effects of antidepressants in patients diagnosed with DM, and eight studies that tested the effect of antidiabetic drugs in patients diagnosed with MDD or BD. Most studies published in the last two decades did not report a positive effect of antidepressants on glycemic control in patients with DM. On the other hand, antidiabetic drugs seem to have a positive effect on the treatment of MDD and BD.
While effect of antidepressants on glycemic control in patients with DM is still controversial, the use of antidiabetic drugs may be a promising strategy for patients with MDD or BD. Prospective studies are still needed.Key pointsMood disorders in patients with DM affect glycemic control, potentially increasing mortality risk.The effect of antidepressants on glycemic control in patients with DM is still controversial. The coexistence of complicated DM and a mood disorders would require a careful, individualised, and comprehensive evaluation.Insulin resistance may increase the risk of depressive symptoms and is associated with worse outcomes in BD.The use antidiabetic drugs may be a promising strategy for patients with MDD or BD. However, prospective trials are needed to prove a potential antidepressant activity of antidiabetic drugs.
本文旨在全面、批判性地综述糖尿病(DM)与心境障碍(即重度抑郁障碍[MDD]和双相障碍[BD])之间关联的现有证据,并探讨治疗机遇。
我们在 MEDLINE(通过 Ovid)中检索了过去 20 年发表的评估用于治疗 DM 或心境障碍的药物再利用方法的安慰剂对照临床试验。
我们发现了 7 项旨在验证抗抑郁药在确诊为 DM 的患者中的疗效的研究,以及 8 项测试抗糖尿病药物在确诊为 MDD 或 BD 的患者中的疗效的研究。过去二十年发表的大多数研究并未报告抗抑郁药对 DM 患者血糖控制的积极影响。另一方面,抗糖尿病药物似乎对 MDD 和 BD 的治疗有积极影响。
尽管抗抑郁药对 DM 患者血糖控制的影响仍存在争议,但使用抗糖尿病药物可能是 MDD 或 BD 患者的一种有前途的策略。仍需要前瞻性研究。
DM 患者的心境障碍会影响血糖控制,可能增加死亡风险。
抗抑郁药对 DM 患者血糖控制的影响仍存在争议。合并复杂的 DM 和心境障碍需要仔细、个体化和全面的评估。
胰岛素抵抗可能增加抑郁症状的风险,并与 BD 的预后较差相关。
使用抗糖尿病药物可能是 MDD 或 BD 患者的一种有前途的策略。然而,需要前瞻性试验来证明抗糖尿病药物的潜在抗抑郁活性。